Concurrent TERT alterations were only identified in EGRF‐LFD carriers with glioblastoma and melanoma while concurrent TP53 alterations were only identified in EGRF‐LFD carriers with lung cancer and colorectal cancer. The gene discussed is TP53; the disease is lung carcinoma.